vendredi 15 février 2013

Hybrigenics inecalcitol to present the results at the annual meeting of the American Society of Clinical Oncology

February 13, 2013
At the meeting of ASCO, Hybrigenics report a completely new aspect to the rapid onset of action of combined treatment: 43 p. % of patients showing a prostate specific antigen decreased by at least 30 % within three weeks ). In addition to the previously indicated high maximum tolerated dose and an excellent overall response rate , a period of rapid action justifies the preparation of the next phase of development: the start of a Phase IIb study.‘As we continue to support high-quality radiation therapy for each patient in the fight against cancer, AAPM is committed to identifying and implementing opportunities to improve safety,’ says Dr. Herman, professor and director of the Division of Medical Physics at the Department of Radiation Oncology at the Mayo Clinic. ‘We will achieve this through the performance, improving the quality of procedures in a practical way for the treatment team, helping to facilitate uniform, national radiation event reports, and continue to identify and overcome obstacles to improving safety.
We believe this is the speed of action of inecalcitol the more remarkable,’ said Dr. Jean-François Dufour-Lamartine, Hybrigenics Chief Medical Officer. ‘These data suggest that the anti-proliferative activity of daily inecalcitol effectively completed the initial cytotoxic effect of Taxotere .’
Hybrigenics , a biopharmaceutical company listed on Alternext in Paris, with an emphasis on research and development of new therapies, today announced that the full results of positive Phase IIa studies of daily oral tolerance inecalcitol neuter clinic patients resistant, in combination with the standard three-weekly regimen Taxotere , chemotherapy will be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on June 5.